Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Income from Continuing Operations (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Income from Continuing Operations readings, the most recent being 7985.0 for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 65.38% to 7985.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 20383.0, a 116.33% increase, with the full-year FY2024 number at 131498.0, down 12.05% from a year prior.
  • Income from Continuing Operations hit 7985.0 in Q3 2025 for Goldenwell Biotech, down from 5220.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 67965.0 in Q4 2024 to a low of 920332.0 in Q4 2022.
  • Median Income from Continuing Operations over the past 5 years was 27084.0 (2023), compared with a mean of 68627.53.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 16234.25% in 2021 and later skyrocketed 426.77% in 2024.
  • Goldenwell Biotech's Income from Continuing Operations stood at 29554.0 in 2021, then plummeted by 3014.07% to 920332.0 in 2022, then skyrocketed by 97.74% to 20799.0 in 2023, then skyrocketed by 426.77% to 67965.0 in 2024, then crashed by 111.75% to 7985.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 7985.0 (Q3 2025), 5220.0 (Q2 2025), and 34377.0 (Q1 2025) per Business Quant data.